ClinicalTrials.gg
CompletedNCT05634811Updated May 7, 2026Results posted

Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children

A Phase 3 interventional study of VLA15 and Normal Saline in Lyme Disease, sponsored by Pfizer. Completed at 65 sites in United States. Open to participants aged 5 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-07.

Sponsored by Pfizer · Phase 3, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,547
Allocation
Randomized
Ages
5 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Lyme Disease with a site in United States — 15 open to participants now, 17 under way, 2 of them phase 3. Lyme Disease · United States.

Enrollment
3rd of 33
3,547 · median 72
Started
2022
with 3 others
Phase 3
10 of 54
1 open now
Registered
42nd of 54
by date
Lead sponsor
8 of 54
Pfizer

Among the 54 studies in Lyme Disease with a site in United States, this one is the 3rd largest by enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2022, is one of 10 in phase 3, and was the 42nd registered.

Lyme Disease

98 studies on the registry are indexed under Lyme Disease; 27 are open to participants now.

Browse Lyme Disease studies →

Open to participants now

15 of the 54 studies in Lyme Disease with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Lyme Disease studies recruiting now, 11 (61%) set no upper age limit and 3 (17%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 5 Years to 17 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Lyme Disease with a site in United States, or all of them as a file.
02

Study summary

This study is to understand if the study vaccine (called VLA15) is safe in healthy children.

We are looking for children who:

  • are healthy
  • are age 5 through 17
  • have not been diagnosed with any form of Lyme disease in the past
  • have not received any vaccines for Lyme disease in the past

Lyme disease happens most often in children of this age. The study vaccine may be used potentially to help prevent Lyme disease. The goal of this study is to get more information about the safety of the study vaccine in this age group.

Participants will be in this study for about 2 years. During that time, they will receive VLA15 or placebo (sterile saltwater solution) by a "shot" in the arm. We will compare experience of children receiving VLA15 to those receiving the placebo. Participants will not know whether they get VLA15 or placebo.

Everyone participating in this study will:

  • get the shots in a clinic or in a hospital office
  • receive a total of 4 shots
  • receive the first 3 shots within 6 months
  • receive the last shot about 1 year afterwards
  • need to come to the trial site for 6 planned visits; 4 of these are vaccination visits and 2 are follow-up visits. We will contact you by phone 1 time every year during the study to monitor your experience. You may have extra visits if you experience a severe reaction after a vaccine dose.
03

Conditions studied

  • Lyme Disease

Keywords

  • Borreliosis
  • Borrelia burgdorferi
  • Spirochetes
  • Vector-Borne Disease
  • Lyme Disease Vaccine
  • VLA15
  • Outer Surface Protein A (OspA)
  • Ticks
04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy participants at enrollment who are determined to be eligible for inclusion in the study. Participants with preexisting chronic medical conditions determined to be stable may be included.
  • Participants and/or participants' parent(s)/guardian who are willing and able to comply with all scheduled visits, study procedures and lifestyle considerations for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Female participants that are pregnant, breastfeeding, or have a positive urine pregnancy test at Visit 1. Sexually active females and fertile males unwilling to use as per protocol.
  • Any to vaccination or vaccine components, including previous anaphylactic reaction to any vaccine or vaccine-related components.
  • Any diagnosis of Lyme disease within the past 3 months.
  • Any history of Lyme arthritis, carditis, neuroborreliosis, or other disseminated Lyme Disease (LD), regardless of when diagnosed.
  • Known tick bite within the past 4 weeks.
  • Congenital or acquired immunodeficiency or other conditions or treatments associated with that would inhibit the ability to mount an immune response to a vaccine.
  • Other medical, psychiatric condition, active suicidal ideation/behavior or lab abnormality which increases risk of study participation or, in investigator's judgment is inappropriate for the study.
  • Receipt of a previous vaccination for LD.
  • Treatment for LD in the 3 months prior to study intervention administration.
  • Receipt of blood/plasma products or immunoglobulins within 6 months before study intervention administration through conclusion of the study.
  • Receipt of systemic for ≥14 days within 28 days before study intervention administration. Inhaled/nebulized, intra-articular, intrabursal, or topical corticosteroids are permitted.
  • Receipt of chronic systemic treatment with other known immunosuppressant medications, or radiotherapy, within 6 months before study intervention administration.
  • Current use of any prohibited concomitant medication(s) or participants unwilling/unable to use a permitted concomitant medication(s).
  • Participation in other studies involving drugs/vaccines/devices within 28 days prior to study entry and/or during study participation (observational studies are acceptable).
  • Investigator site staff, sponsor/sponsor delegates directly involved in the conduct of the study and their family members; site staff supervised by the investigator and their family members.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
3,547 participants (actual)

Study arms

  • Experimental
    VLA15

    Participants will receive 6-valent OspA-based Lyme disease vaccine (VLA15).

    Biological: VLA15

  • Placebo comparator
    Normal Saline (Placebo)

    Participants will receive 0.9% sodium chloride solution for injection

    Other: Normal Saline

Interventions

  • BiologicalVLA15

    6-valent OspA-based Lyme disease vaccine

    Also known as: PF-07307405

  • OtherNormal Saline

    0.9% sodium chloride solution for injection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 1

    Local reactions included pain at injection site, redness and swelling and were recorded by participants in the electronic dairy (e-diary) or by investigators in case report form (CRF) after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol based on Center for Biologics Evaluation and Research (CBER) toxicity guidelines. Percentage of participants with at least 1 local reaction of any grade were reported in this outcome measure.

    Time frame: From Day 1 through Day 7 after Study Vaccination 1 (Vaccination on Day 1, Month 0)

  2. Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 2

    Local reactions included pain at injection site, redness and swelling and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 local reaction of any grade were reported in this outcome measure.

    Time frame: From Day 1 through Day 7 after Study Vaccination 2 (Vaccination on Day 1, Month 2)

  3. Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 3

    Local reactions included pain at injection site, redness and swelling and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 local reaction of any grade were reported in this outcome measure.

    Time frame: From Day 1 through Day 7 after Study Vaccination 3 (Vaccination on Day 1, Month 6)

  4. Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 4 (Booster Dose)

    Local reactions included pain at injection site, redness and swelling and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 local reaction of any grade were reported in this outcome measure.

    Time frame: From Day 1 through Day 7 after Study Vaccination 4 (Vaccination on Day 1, Month 18)

  5. Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days After Any Study Vaccination

    Local reactions included pain at injection site, redness and swelling and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 local reaction of any grade were reported in this outcome measure.

    Time frame: From Day 1 through Day 7 after any study vaccination

  6. Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 1

    Systemic events included fever, fatigue, headache, muscle pain and joint pain and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 systemic event of any grade were reported in this outcome measure.

    Time frame: From Day 1 through Day 7 after Study Vaccination 1 (Vaccination on Day 1, Month 0)

  7. Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 2

    Systemic events included fever, fatigue, headache, muscle pain and joint pain and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 systemic event of any grade were reported in this outcome measure.

    Time frame: From Day 1 through Day 7 after Study Vaccination 2 (Vaccination on Day 1, Month 2)

  8. Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 3

    Systemic events included fever, fatigue, headache, muscle pain and joint pain and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 systemic event of any grade were reported in this outcome measure.

    Time frame: From Day 1 through Day 7 after Study Vaccination 3 (Vaccination on Day 1, Month 6)

  9. Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 4 (Booster Dose)

    Systemic events included fever, fatigue, headache, muscle pain and joint pain and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 systemic event of any grade were reported in this outcome measure.

    Time frame: From Day 1 through Day 7 after Study Vaccination 4 (Vaccination on Day 1, Month 18)

  10. Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days After Any Study Vaccination

    Systemic events included fever, fatigue, headache, muscle pain and joint pain and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 systemic event of any grade were reported in this outcome measure.

    Time frame: From Day 1 through Day 7 after any study vaccination

  11. Percentage of Participants With AEs Through 1 Month Following Study Vaccination 1

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) after dose 1 were included in this outcome measure. AEs included both serious AEs (SAEs) and non-SAEs.

    Time frame: From Day 1 through 1 Month after Study Vaccination 1 (Vaccination on Day 1, Month 0)

  12. Percentage of Participants With AEs Through 1 Month Following Study Vaccination 2

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) after dose 2 were included in this outcome measure. AEs included both SAEs and non-SAEs.

    Time frame: From Day 1 through 1 Month after Study Vaccination 2 (Vaccination on Day 1, Month 2)

  13. Percentage of Participants With AEs Through 1 Month Following Study Vaccination 3

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) after dose 3 were included in this outcome measure. AEs included both SAEs and non-SAEs.

    Time frame: From Day 1 through 1 Month after Study Vaccination 3 (Vaccination on Day 1, Month 6)

  14. Percentage of Participants With AEs Through 1 Month Following Study Vaccination 4 (Booster Dose)

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) after dose 4 were included in this outcome measure. AEs included both SAEs and non-SAEs.

    Time frame: From Day 1 through 1 Month after Study Vaccination 4 (Vaccination on Day 1, Month 18)

  15. Percentage of Participants With AEs Through 1 Month Following Any Study Vaccination

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) after any dose were included in this outcome measure.

    Time frame: From Day 1 through 1 Month after any study vaccination

  16. Percentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMCs) Throughout the Study

    An NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects. NDCMCs included conditions that were undiagnosed prior to study entry (diagnosed while in the study and confirmed not to be a preexisting condition) and that were not considered temporary conditions based upon the expected natural history of the condition. An NDCMC was not reported on AE CRF.

    Time frame: Throughout the study (from study vaccination 1 through 6 months post study Vaccination 4 [Booster dose]: maximum up to 24 months)

  17. Percentage of Participants With Serious Adverse Events (SAEs) Throughout the Study

    An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, any other important medical event.

    Time frame: Throughout the study (from study vaccination 1 through 6 months post study Vaccination 4 [Booster dose]: maximum up to 24 months)

07

Results

Posted May 7, 2026

Participant flow

A total of 3646 participants were enrolled, of which 3547 participants were randomized.

Participant flow — Overall Study
MilestoneVLA15: 5 to 11 YearsPlacebo: 5 to 11 YearsVLA15: 12 to 17 YearsPlacebo: 12 to 17 Years
Started14324751221419
Vaccinated14294671219418
Completed1209389997350
Not completed2238622469
Withdrew: Physician decision9352
Withdrew: Withdrawal by subject45124916
Withdrew: No longer met eligibility criteria3071
Withdrew: Withdrawal by parent or guardian50184211
Withdrew: Lost to follow-up964310634
Withdrew: Medication error without associated adverse event2000
Withdrew: Other5130
Withdrew: Randomized but not treated3821
Withdrew: Adverse event101104

Outcome measures

PrimaryPercentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 1

Local reactions included pain at injection site, redness and swelling and were recorded by participants in the electronic dairy (e-diary) or by investigators in case report form (CRF) after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol based on Center for Biologics Evaluation and Research (CBER) toxicity guidelines. Percentage of participants with at least 1 local reaction of any grade were reported in this outcome measure.

Time frame:
From Day 1 through Day 7 after Study Vaccination 1 (Vaccination on Day 1, Month 0)
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 1
Percentage of participantsVLA15: 5 to 11 YearsPlacebo: 5 to 11 YearsVLA15: 12 to 17 YearsPlacebo: 12 to 17 Years
Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 180.8 (78.6 to 82.8)34.8 (30.4 to 39.4)80.6 (78.3 to 82.8)14.6 (11.4 to 18.4)
PrimaryPercentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 2

Local reactions included pain at injection site, redness and swelling and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 local reaction of any grade were reported in this outcome measure.

Time frame:
From Day 1 through Day 7 after Study Vaccination 2 (Vaccination on Day 1, Month 2)
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 2
Percentage of participantsVLA15: 5 to 11 YearsPlacebo: 5 to 11 YearsVLA15: 12 to 17 YearsPlacebo: 12 to 17 Years
Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 272.6 (70.0 to 75.0)29.0 (24.8 to 33.5)71.4 (68.6 to 74.0)11.7 (8.6 to 15.3)
PrimaryPercentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 3

Local reactions included pain at injection site, redness and swelling and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 local reaction of any grade were reported in this outcome measure.

Time frame:
From Day 1 through Day 7 after Study Vaccination 3 (Vaccination on Day 1, Month 6)
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 3
Percentage of participantsVLA15: 5 to 11 YearsPlacebo: 5 to 11 YearsVLA15: 12 to 17 YearsPlacebo: 12 to 17 Years
Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 373.5 (70.9 to 75.9)25.1 (20.8 to 29.7)69.6 (66.8 to 72.4)9.7 (6.9 to 13.1)
PrimaryPercentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 4 (Booster Dose)

Local reactions included pain at injection site, redness and swelling and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 local reaction of any grade were reported in this outcome measure.

Time frame:
From Day 1 through Day 7 after Study Vaccination 4 (Vaccination on Day 1, Month 18)
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 4 (Booster Dose)
Percentage of participantsVLA15: 5 to 11 YearsPlacebo: 5 to 11 YearsVLA15: 12 to 17 YearsPlacebo: 12 to 17 Years
Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 4 (Booster Dose)77.0 (74.5 to 79.4)24.7 (20.5 to 29.4)71.6 (68.7 to 74.4)11.7 (8.6 to 15.6)
PrimaryPercentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days After Any Study Vaccination

Local reactions included pain at injection site, redness and swelling and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 local reaction of any grade were reported in this outcome measure.

Time frame:
From Day 1 through Day 7 after any study vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days After Any Study Vaccination
Percentage of participantsVLA15: 5 to 11 YearsPlacebo: 5 to 11 YearsVLA15: 12 to 17 YearsPlacebo: 12 to 17 Years
Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days After Any Study Vaccination88.3 (86.5 to 89.9)56.0 (51.4 to 60.6)90.0 (88.2 to 91.6)31.6 (27.1 to 36.3)
PrimaryPercentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 1

Systemic events included fever, fatigue, headache, muscle pain and joint pain and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 systemic event of any grade were reported in this outcome measure.

Time frame:
From Day 1 through Day 7 after Study Vaccination 1 (Vaccination on Day 1, Month 0)
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 1
Percentage of participantsVLA15: 5 to 11 YearsPlacebo: 5 to 11 YearsVLA15: 12 to 17 YearsPlacebo: 12 to 17 Years
Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 156.0 (53.3 to 58.6)41.0 (36.5 to 45.7)62.2 (59.4 to 64.9)48.8 (43.8 to 53.7)
PrimaryPercentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 2

Systemic events included fever, fatigue, headache, muscle pain and joint pain and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 systemic event of any grade were reported in this outcome measure.

Time frame:
From Day 1 through Day 7 after Study Vaccination 2 (Vaccination on Day 1, Month 2)
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 2
Percentage of participantsVLA15: 5 to 11 YearsPlacebo: 5 to 11 YearsVLA15: 12 to 17 YearsPlacebo: 12 to 17 Years
Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 248.1 (45.3 to 50.8)30.2 (25.9 to 34.8)55.3 (52.3 to 58.2)31.6 (27.0 to 36.5)
PrimaryPercentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 3

Systemic events included fever, fatigue, headache, muscle pain and joint pain and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 systemic event of any grade were reported in this outcome measure.

Time frame:
From Day 1 through Day 7 after Study Vaccination 3 (Vaccination on Day 1, Month 6)
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 3
Percentage of participantsVLA15: 5 to 11 YearsPlacebo: 5 to 11 YearsVLA15: 12 to 17 YearsPlacebo: 12 to 17 Years
Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 347.5 (44.6 to 50.3)27.6 (23.2 to 32.3)51.6 (48.5 to 54.6)26.1 (21.7 to 30.9)
PrimaryPercentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 4 (Booster Dose)

Systemic events included fever, fatigue, headache, muscle pain and joint pain and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 systemic event of any grade were reported in this outcome measure.

Time frame:
From Day 1 through Day 7 after Study Vaccination 4 (Vaccination on Day 1, Month 18)
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 4 (Booster Dose)
Percentage of participantsVLA15: 5 to 11 YearsPlacebo: 5 to 11 YearsVLA15: 12 to 17 YearsPlacebo: 12 to 17 Years
Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 4 (Booster Dose)53.5 (50.6 to 56.4)28.1 (23.7 to 32.9)54.8 (51.6 to 57.9)28.4 (23.7 to 33.4)
PrimaryPercentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days After Any Study Vaccination

Systemic events included fever, fatigue, headache, muscle pain and joint pain and were recorded by participants in the e-diary or by investigators in CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol based on CBER toxicity guidelines. Percentage of participants with at least 1 systemic event of any grade were reported in this outcome measure.

Time frame:
From Day 1 through Day 7 after any study vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days After Any Study Vaccination
Percentage of participantsVLA15: 5 to 11 YearsPlacebo: 5 to 11 YearsVLA15: 12 to 17 YearsPlacebo: 12 to 17 Years
Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days After Any Study Vaccination77.8 (75.5 to 79.9)60.1 (55.5 to 64.6)82.1 (79.8 to 84.2)63.1 (58.3 to 67.8)
PrimaryPercentage of Participants With AEs Through 1 Month Following Study Vaccination 1

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) after dose 1 were included in this outcome measure. AEs included both serious AEs (SAEs) and non-SAEs.

Time frame:
From Day 1 through 1 Month after Study Vaccination 1 (Vaccination on Day 1, Month 0)
Reported as:
Number · Percentage of participants
Percentage of Participants With AEs Through 1 Month Following Study Vaccination 1
Percentage of participantsVLA15: 5 to 11 YearsPlacebo: 5 to 11 YearsVLA15: 12 to 17 YearsPlacebo: 12 to 17 Years
Percentage of Participants With AEs Through 1 Month Following Study Vaccination 13.4 (2.6 to 4.5)3.0 (1.6 to 5.0)3.1 (2.2 to 4.3)4.5 (2.8 to 7.0)
PrimaryPercentage of Participants With AEs Through 1 Month Following Study Vaccination 2

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) after dose 2 were included in this outcome measure. AEs included both SAEs and non-SAEs.

Time frame:
From Day 1 through 1 Month after Study Vaccination 2 (Vaccination on Day 1, Month 2)
Reported as:
Number · Percentage of participants
Percentage of Participants With AEs Through 1 Month Following Study Vaccination 2
Percentage of participantsVLA15: 5 to 11 YearsPlacebo: 5 to 11 YearsVLA15: 12 to 17 YearsPlacebo: 12 to 17 Years
Percentage of Participants With AEs Through 1 Month Following Study Vaccination 22.4 (1.7 to 3.4)2.2 (1.1 to 4.0)1.5 (0.9 to 2.4)2.2 (1.0 to 4.2)
PrimaryPercentage of Participants With AEs Through 1 Month Following Study Vaccination 3

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) after dose 3 were included in this outcome measure. AEs included both SAEs and non-SAEs.

Time frame:
From Day 1 through 1 Month after Study Vaccination 3 (Vaccination on Day 1, Month 6)
Reported as:
Number · Percentage of participants
Percentage of Participants With AEs Through 1 Month Following Study Vaccination 3
Percentage of participantsVLA15: 5 to 11 YearsPlacebo: 5 to 11 YearsVLA15: 12 to 17 YearsPlacebo: 12 to 17 Years
Percentage of Participants With AEs Through 1 Month Following Study Vaccination 34.6 (3.5 to 5.8)3.5 (2.0 to 5.7)4.6 (3.5 to 6.0)4.3 (2.5 to 6.8)
PrimaryPercentage of Participants With AEs Through 1 Month Following Study Vaccination 4 (Booster Dose)

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) after dose 4 were included in this outcome measure. AEs included both SAEs and non-SAEs.

Time frame:
From Day 1 through 1 Month after Study Vaccination 4 (Vaccination on Day 1, Month 18)
Reported as:
Number · Percentage of participants
Percentage of Participants With AEs Through 1 Month Following Study Vaccination 4 (Booster Dose)
Percentage of participantsVLA15: 5 to 11 YearsPlacebo: 5 to 11 YearsVLA15: 12 to 17 YearsPlacebo: 12 to 17 Years
Percentage of Participants With AEs Through 1 Month Following Study Vaccination 4 (Booster Dose)4.1 (3.0 to 5.3)2.5 (1.2 to 4.6)4.1 (3.0 to 5.5)4.7 (2.8 to 7.5)
PrimaryPercentage of Participants With AEs Through 1 Month Following Any Study Vaccination

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) after any dose were included in this outcome measure.

Time frame:
From Day 1 through 1 Month after any study vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With AEs Through 1 Month Following Any Study Vaccination
Percentage of participantsVLA15: 5 to 11 YearsPlacebo: 5 to 11 YearsVLA15: 12 to 17 YearsPlacebo: 12 to 17 Years
Percentage of Participants With AEs Through 1 Month Following Any Study Vaccination11.7 (10.1 to 13.5)8.6 (6.2 to 11.5)11.2 (9.5 to 13.1)12.2 (9.2 to 15.7)
PrimaryPercentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMCs) Throughout the Study

An NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects. NDCMCs included conditions that were undiagnosed prior to study entry (diagnosed while in the study and confirmed not to be a preexisting condition) and that were not considered temporary conditions based upon the expected natural history of the condition. An NDCMC was not reported on AE CRF.

Time frame:
Throughout the study (from study vaccination 1 through 6 months post study Vaccination 4 [Booster dose]: maximum up to 24 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMCs) Throughout the Study
Percentage of participantsVLA15: 5 to 11 YearsPlacebo: 5 to 11 YearsVLA15: 12 to 17 YearsPlacebo: 12 to 17 Years
Percentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMCs) Throughout the Study2.7 (1.9 to 3.7)1.9 (0.9 to 3.6)2.1 (1.4 to 3.1)3.3 (1.8 to 5.6)
PrimaryPercentage of Participants With Serious Adverse Events (SAEs) Throughout the Study

An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, any other important medical event.

Time frame:
Throughout the study (from study vaccination 1 through 6 months post study Vaccination 4 [Booster dose]: maximum up to 24 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Serious Adverse Events (SAEs) Throughout the Study
Percentage of participantsVLA15: 5 to 11 YearsPlacebo: 5 to 11 YearsVLA15: 12 to 17 YearsPlacebo: 12 to 17 Years
Percentage of Participants With Serious Adverse Events (SAEs) Throughout the Study1.0 (0.6 to 1.7)0.9 (0.2 to 2.2)2.2 (1.5 to 3.2)2.4 (1.2 to 4.4)

Adverse events

Collected over Local reactions and systemic events: Day 1 to Day 7 after each study vaccination; SAEs, All-cause mortality: Throughout the study (from study Vaccination 1 through 6 months post study Vaccination 4 [Booster dose]: maximum up to 24 months); Other AEs: From Day 1 through 1 Month after any study vaccination. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VLA15: 5 to 11 Years0/1,429 (0%)15/1,429 (1%)1,290/1,429 (90.3%)
Placebo: 5 to 11 Years0/467 (0%)4/467 (0.9%)341/467 (73%)
VLA15: 12 to 17 Years0/1,219 (0%)27/1,219 (2.2%)1,121/1,219 (92%)
Placebo: 12 to 17 Years1/418 (0.2%)10/418 (2.4%)295/418 (70.6%)
VLA15: Overall0/2,648 (0%)42/2,648 (1.6%)2,411/2,648 (91%)
Placebo: Overall1/885 (0.1%)14/885 (1.6%)636/885 (71.9%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventVLA15: 5 to 11 YearsPlacebo: 5 to 11 YearsVLA15: 12 to 17 YearsPlacebo: 12 to 17 YearsVLA15: OverallPlacebo: Overall
Diabetic ketoacidosisMetabolism and nutrition disorders0/14290/4670/12192/4180/26482/885
Suicidal ideationPsychiatric disorders0/14291/4673/12190/4183/26481/885
Mycoplasma infectionInfections and infestations0/14290/4670/12191/4180/26481/885
OsteomyelitisInfections and infestations0/14290/4670/12191/4180/26481/885
PharyngitisInfections and infestations0/14290/4670/12191/4180/26481/885
TonsillitisInfections and infestations0/14290/4670/12191/4180/26481/885
Tibia fractureInjury, poisoning and procedural complications0/14290/4671/12191/4181/26481/885
Type 1 diabetes mellitusMetabolism and nutrition disorders2/14290/4670/12191/4182/26481/885
EpilepsyNervous system disorders0/14290/4670/12191/4180/26481/885
Drug abusePsychiatric disorders0/14290/4670/12191/4180/26481/885
Most frequent other events
Showing 10 of 18
Most frequent other events
EventVLA15: 5 to 11 YearsPlacebo: 5 to 11 YearsVLA15: 12 to 17 YearsPlacebo: 12 to 17 YearsVLA15: OverallPlacebo: Overall
Injection site pain (PAIN AT INJECTION SITE)General disorders1245/1429250/4671084/1219130/4182329/2648380/885
Fatigue (FATIGUE)General disorders875/1429219/467769/1219193/4181644/2648412/885
Erythema (REDNESS)Skin and subcutaneous tissue disorders891/142976/467305/121912/4181196/264888/885
Headache (HEADACHE)Nervous system disorders750/1429192/467734/1219180/4181484/2648372/885
Swelling (SWELLING)General disorders752/142945/467277/12197/4181029/264852/885
Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders717/1429112/467637/1219110/4181354/2648222/885
Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders375/142964/467353/121965/418728/2648129/885
Pyrexia (FEVER)General disorders193/142929/46789/121919/418282/264848/885
Upper respiratory tract infectionInfections and infestations31/142913/46724/121916/41855/264829/885
Pharyngitis streptococcalInfections and infestations47/142914/46712/12195/41859/264819/885

Baseline characteristics

Safety population included all enrolled participants who received at least 1 dose of the study intervention.

Age, Continuous
Age, Continuous(Years)VLA15: 5 to 11 YearsPlacebo: 5 to 11 YearsVLA15: 12 to 17 YearsPlacebo: 12 to 17 YearsTotal
Mean8.2 ± 2.08.2 ± 2.014.3 ± 1.714.3 ± 1.711 ± 3.5
Sex: Female, Male
Sex: Female, Male(Participants)VLA15: 5 to 11 YearsPlacebo: 5 to 11 YearsVLA15: 12 to 17 YearsPlacebo: 12 to 17 YearsTotal
Female6532145961821645
Male7762536232361888
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)VLA15: 5 to 11 YearsPlacebo: 5 to 11 YearsVLA15: 12 to 17 YearsPlacebo: 12 to 17 YearsTotal
Hispanic or Latino2407526890673
Not Hispanic or Latino11813919443272843
Unknown or Not Reported817117
Race (NIH/OMB)
Race (NIH/OMB)(Participants)VLA15: 5 to 11 YearsPlacebo: 5 to 11 YearsVLA15: 12 to 17 YearsPlacebo: 12 to 17 YearsTotal
American Indian or Alaska Native22509
Asian3212271283
Native Hawaiian or Other Pacific Islander20204
Black or African American2629920872641
White10813429473202690
More than one race37820974
Unknown or Not Reported13410532
08

Study locations

65 sites
  • UAB Child Health Research Unit (CHRU)
    Birmingham, Alabama 35233, United States
  • University of Alabama at Birmingham - School of Medicine
    Birmingham, Alabama 35233, United States
  • Lakeview Clinical Research
    Guntersville, Alabama 35976, United States
  • Coast Clinical Research, LLC
    Bellflower, California 90706, United States
  • Apex Research Group LLC
    Fair Oaks, California 95628, United States
  • New England Research Associates
    Bridgeport, Connecticut 06606, United States
  • Stamford Therapeutics Consortium
    Stamford, Connecticut 06905, United States
  • Children's National Medical Center
    Washington D.C., District of Columbia 20010, United States
  • Bio-Medical Research LLC
    Miami, Florida 33144, United States
  • GCP Research, Global Clinical professionals
    St. Petersburg, Florida 33705, United States
  • MOORE Clinical Research, Inc. d/b/a TrueBlue Clinical Research
    Tampa, Florida 33609, United States
  • ForCare Clinical Research
    Tampa, Florida 33613, United States
  • Tekton Research, LLC.
    Chamblee, Georgia 30341, United States
  • ASR, LLC
    Boise, Idaho 83702, United States
  • Clinical Research Prime
    Idaho Falls, Idaho 83404, United States
  • Clinical Research Prime Rexburg
    Rexburg, Idaho 83440, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • AMR Clinical
    El Dorado, Kansas 67042, United States
  • AMR Clinical
    Wichita, Kansas 67207, United States
  • Kentucky Pediatric/ Adult Research
    Bardstown, Kentucky 40004, United States
  • All Children Pediatrics
    Louisville, Kentucky 40243, United States
  • MD Medical Research
    Oxon Hill, Maryland 20745, United States
  • White Oak Pediatrics
    Silver Spring, Maryland 20904, United States
  • Sisu BHR
    Springfield, Massachusetts 01103, United States
  • Michigan Center of Medical Research (MICHMER)
    Bingham Farms, Michigan 48025, United States
  • Vida Clinical Studies, LLC
    Dearborn Heights, Michigan 48127, United States
  • Great Lakes Research Institute
    Southfield, Michigan 48075, United States
  • Clinical Research Institute
    Minneapolis, Minnesota 55402, United States
  • Velocity Clinical Research, Omaha
    Omaha, Nebraska 68134, United States
  • Hassman Research Institute
    Marlton, New Jersey 08053, United States
  • Rutgers University
    New Brunswick, New Jersey 08901, United States
  • IMA Clinical Research Warren
    Warren Township, New Jersey 07059, United States
  • Velocity Clinical Research, Binghamton
    Binghamton, New York 13905, United States
  • Buffalo Clinical and Translational Research Center
    Buffalo, New York 14203, United States
  • Advanced Specialty Care
    Commack, New York 11725, United States
  • Smith Allergy and Asthma Specialists
    Cortland, New York 13045, United States
  • Stony Brook Medicine Clinical Research Center
    East Setauket, New York 11733, United States
  • Upstate Global Health Institute
    East Syracuse, New York 13057, United States
  • Southampton Hospital
    Hampton Bays, New York 11946, United States
  • Smith Allergy & Asthma Specialists
    Horseheads, New York 14845, United States
  • NYU Langone Hospital - Long Island
    Mineola, New York 11501, United States
  • DiGiovanna Institute for Medical Education & Research
    North Massapequa, New York 11758, United States
  • Rochester Clinical Research, LLC
    Rochester, New York 14609, United States
  • Stony Brook University
    Stony Brook, New York 11794, United States
  • Prime Global Research
    The Bronx, New York 10456, United States
  • Advantage Clinical Trials
    The Bronx, New York 10467, United States
  • Velocity Clinical Research, Vestal
    Vestal, New York 13850, United States
  • Centricity Research Columbus Ohio Multispecialty
    Columbus, Ohio 43213, United States
  • Allegheny Health and Wellness Pavilion
    Erie, Pennsylvania 16506, United States
  • Central Erie Primary Care
    Erie, Pennsylvania 16508, United States
  • Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18)
    Pittsburgh, Pennsylvania 15236, United States
  • Northeast Clinical Trials Group
    Scranton, Pennsylvania 18510, United States
  • Coastal Carolina Research Center
    North Charleston, South Carolina 29405, United States
  • Benchmark Research
    Austin, Texas 78705, United States
  • Benchmark Research
    Fort Worth, Texas 76135, United States
  • Texas Health Resources
    Fort Worth, Texas 76135, United States
  • C & R Research Services USA
    Houston, Texas 77022, United States
  • DM Clinical Research - Kool Kids Pediatrics
    Houston, Texas 77065, United States
  • Research Your Health
    Plano, Texas 75093, United States
  • Sun Research Institute
    San Antonio, Texas 78215, United States
  • Velocity Clinical Research, Salt Lake City
    West Jordan, Utah 84088, United States
  • Pediatric Research of Charlottesville, LLC
    Charlottesville, Virginia 22902, United States
  • Clinical Research Partners, LLC
    Richmond, Virginia 23226, United States
  • Frontier Clinical research
    Kingwood, West Virginia 26537, United States
  • Preston Healthcare Services
    Kingwood, West Virginia 26537, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Jul 2025, 31 months.

Results were first posted in May 2026, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2022
First posted
Dec 2, 2022
StartActual
Dec 12, 2022
Primary completionActual
Jul 21, 2025
CompletionActual
Jul 21, 2025
Results first posted
May 7, 2026
Last update
May 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05634811
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 2, 2022
Start date
Dec 12, 2022
Primary completion
Jul 21, 2025
Completion
Jul 21, 2025
Results posted
May 7, 2026
Last update
May 7, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VLA15

Start the discussion